Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 805 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Regulatory Filings Classification · 87% confidence The document is a press release announcing the FDA acceptance of a supplemental New Drug Application (sNDA) for Joenja® (leniolisib) in pediatric patients. There are no financial statements, no AGM materials, no earnings data or management discussion, and no shareholder or capital market activity. It is a regulatory announcement about drug approval rather than a financial or governance filing. This fits the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-06-04 Dutch
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing the U.S. FDA’s acceptance of a supplemental New Drug Application (sNDA) for Joenja®, with no substantive financial statements or meeting materials. It is not a report itself but a regulatory announcement regarding FDA acceptance. Therefore, it best fits the generic regulatory announcement category.
2026-06-04 English
6-K
Regulatory Filings Classification · 80% confidence The document is a U.S. SEC Form 6-K by a foreign private issuer, furnishing a press release (Exhibit 99.1) announcing FDA acceptance of an sNDA. It is not a financial report (no statements), not earnings information, not management/board change, not an annual or interim report, nor a proxy, dividend or M&A filing. It is a regulatory announcement submitted under the Exchange Act, so it falls under the general Regulatory Filings category (RNS).
2026-06-04 English
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release announcing the outcomes of the Annual General Meeting of Shareholders (AGA), stating which proposals were approved (e.g., auditor appointment, remuneration policy changes, share issuances, buyback authorization). It provides official voting results from the AGM. This fits the ‘Declaration of Voting Results & Voting Rights Announcements’ category (DVA).
2026-05-29 Dutch
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a press release announcing the results of Pharming Group’s 2026 Annual General Meeting of shareholders, including approved proposals and voting outcomes. It specifically reports on the voting results at an AGM, matching the definition of a Declaration of Voting Results & Voting Rights Announcements.
2026-05-29 English
6-K
Regulatory Filings
2026-05-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.